Bona Releases 2021 Sustainability Report
Bona ®, a global, sustainably-driven company that supplies products for installing, renovating, maintaining and restoring premium floors, today released the results of its 2021 Sustainability Report. The report highlights Bona’s most significant sustainability milestones for the year focused on its commitment to betterment for home, health, and humanity.
“Our commitment and responsible approach to the environment, people and society has remained steadfast for more than 100 years,” said Kerstin Lindell, Chair of the Board, Bona AB. “This past year presented some challenges, including supply chain and raw materials shortages, yet Bona stayed flexible and focused. Thanks to our fantastic team, our promise to deliver the best products and systems to our customers never wavered and we continue to identify more sustainable solutions. The ability to quickly shift, work together, and develop products and offerings despite changing market conditions has been key to our success.”
Sustainable development on the agenda
In 2021, Bona made some significant investments in its commitment to a sustainable future. The first was the introduction of an electric truck to Bona’s transportation fleet in Limburg, Germany. The electric truck will contribute to lower nitrogen dioxide levels in the city of Limburg and to global decarbonization. In Sweden, Bona invested in a geothermal system that will provide Bona’s Malmö facility with geothermal energy offsetting 20 percent of the yearly energy use at the facility. Another significant milestone last year was the purchase of 26,000-square-meters of land to build a new facility in Monroe, North Carolina, USA. The project, which will be completed in 2022, supports more efficient operations and increased internal capabilities allowing Bona US to operate in a more environmentally friendly way.
Björn Johansson Global Environmental Manager at Bona, said, “We continue to take important steps forward by increasing our use of renewable energy, smarter materials and packaging that uses less virgin plastic, and exhaustively researching new and better ingredients for our products. While we still have work to do, 2021 was a year where we made good progress.”
Highlights of the year
Bona’s core offering encourages care, maintenance, and renovation of hard flooring surfaces such as wood and resilient rather than replacing these materials thereby safeguarding the earth’s finite resources. In 2021 Bona produced finishes, stains, and sealers to cover more than 43 million square meters of wood flooring, saving a forest area equal to approximately 32 million square meters. By not cutting down the forest, the same number of trees encapsulates 28,917 tonnes of carbon dioxide (CO2), calculated as 9-ton CO by hectare and year.
Also in 2021, Bona initiated the use of 90 percent post-consumer recycled (PCR) material in its microfiber pads designed for the Bona Spray Mop and Bona Microfiber Mop. Aligning to the company’s goal to use less virgin plastic, this shift is helping divert over 217 tons of plastic waste from being incinerated or going to landfills.
In the autumn of last year, Bona received the Safer Choice Partner of the Year Award from the US Environmental Protection Agency (EPA) for its work innovating better ingredients in its floor cleaning solutions. Since becoming a Safer Choice partner in 2020, Bona has certified 13 products, six of which were certified in 2021.
Other key facts
Additional notable facts from Bona’s 2021 Sustainability report include:
- Five years ago, Bona moved its adhesive product from buckets to a tube packaging called “sausages.” In 2021 Bona reduced its environmental footprint by using sausages rather than buckets and over the past five years Bona has avoided using more than 258,000 buckets which is a carbon savings of 243,281 kg.
- An innovative ergonomic tool was launched 2021 as a new addition to the Bona FlexiSand Pro System. The Bona ErgoEdge is a machine attachment that allows flooring contractors to achieve smooth, efficient sanding in corners and edges of a floor without kneeling or bending by attaching to an existing, standing machine. This innovation saves time and offers a more ergonomic experience for the contractor all while providing a premium floor sanding experience.
- In 2021 Bona released several new products all of which were formulated with Bona’s commitment to greener chemistry including amplified formulas of its Bona Hardwood Floor and Bona Hard-Floor cleaning solutions. The formulations are water-based, biodegradable, meet the U.S. EPA product standards, and are Safer Choice Certified.
- Since 2016, Bona has collaborated with Hand in Hand, a non-governmental organization (NGO) that fights poverty with grassroots entrepreneurship, to increase the quality of life for three villages in India. With the organizations Village Upliftment Program, Bona’s partnership has helped improve living conditions for women and children through education and the creation of new jobs.
About the framework of Bona’s 2021 Sustainability Report
For the fifth year in a row, Bona reported the company's sustainability work in accordance with Swedish law and standards. The 2021 Sustainability Report aligns to the UN Sustainability goals and summarizes the sustainability information in the four areas of environment, social conditions, personnel and respect for human rights and the fight against corruption. View the full report at bona.com/sustainability
About Bona
Bona is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. Bona’s turnover is 3.1bn SEK (EUR 307 million) 2021. The head office is in Malmö, Sweden, and the company is represented globally by its 17 subsidiaries, 70 distributors, 4 production units and 600 employees. For more visit www.bona.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005107/en/
Contact information
Heather Lindemann | Bona
+1 (800) 872-5515
heather.lindemann@bona.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
